All In Biotech

Drug Trial Radar · NCT03438396

A Trial of Tisotumab Vedotin in Cervical Cancer

A Single Arm, Multicenter, International Trial of Tisotumab Vedotin (HuMax®-TF-ADC) in Previously Treated, Recurrent or Metastatic Cervical Cancer

Last checked: Nov 20, 2026Latest source record: Jul 25, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

102

Actual

Start

Jun 12, 2018

Primary completion

Feb 6, 2020

Study completion Aug 2, 2022

Sponsor

Lead sponsor
Seagen Inc.Pfizer (PFE)
Sponsor type
Industry
Collaborators
Genmab; European Network of Gynaecological Oncological Trial Groups (ENGOT); Belgian Gynaecological Oncology Group; Gynecologic Oncology Group
First posted
Feb 19, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A Single arm, Multicenter, International Trial of Tisotumab Vedotin (HuMax®-TF-ADC) in Previously Treated, Recurrent or Metastatic Cervical Cancer.

Conditions

  • Cervical Cancer

Interventions

  • tisotumab vedotinDrug

    All patients will be treated with tisotumab vedotin once every three weeks until progression or toxicity

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With Confirmed Objective Response (OR) as Assessed by the Independent Review Committee (IRC)Time frame: From Day 1 through IRC verified disease progression, initiation of new anticancer therapy, study withdrawal, or death, whichever occurred first (approximately 20 months)

Locations

53 sites in 8 countries. Site status is shown where the registry gives one.

  • University of Alabama

    Birmingham, Alabama

  • Arizona Oncology Associate - Biltmore Cancer Center

    Phoenix, Arizona

  • UCLA Dept. of OBGYN

    Los Angeles, California

  • Southern Baptist Hospital of Florida, Inc

    Jacksonville, Florida

  • University of Miami Miller School of Medicine

    Miami, Florida

  • University of Gynecologic Oncology

    Atlanta, Georgia

  • Community Hospital East

    Indianapolis, Indiana

  • Louisville Oncology

    Louisville, Kentucky

  • Baystate Medical Center

    Springfield, Massachusetts

  • Women's Cancer Center of Nevada

    Las Vegas, Nevada

  • MD Anderson Cancer Center at Cooper University Hospital

    Camden, New Jersey

  • University of New Mexico Comprehensive Cancer Center (UNMCCC)

    Albuquerque, New Mexico

  • University of Cincinnati

    Cincinnati, Ohio

  • The Ohio State University Wexner Medical Center

    Hilliard, Ohio

  • Stephenson Cancer Center

    Oklahoma City, Oklahoma

  • Oklahoma Cancer Specialists and Research Institute, LLC

    Tulsa, Oklahoma

  • Abington Memorial Hospital

    Willow Grove, Pennsylvania

  • Bon Secours Saint Francis Cancer Center

    Greenville, South Carolina

  • UT Health McGovern Medical School

    Houston, Texas

  • Froedtert & Medical College Clinics

    Milwaukee, Wisconsin

  • AZ Sint-Jan Brugge-Oostende av

    Bruges, Belgium

  • Cliniques universitaires Saint-Luc

    Brussels, Belgium

  • Grand Hôpital de Charleroi

    Charleroi, Belgium

  • Algemeen Ziekenhuis Maria MiddelaresMedical Oncology - IKG

    Ghent, Belgium

  • Universitair Ziekenhuis Gent

    Ghent, Belgium

  • UZLeuvenGynaecologische oncologie

    Leuven, Belgium

  • Centre Hospitalier de l'Ardenne

    Libramont, Belgium

  • CHC SAINT Montlegia

    Liège, Belgium

  • CHU de LIEGE/ Oncologie Médicale, domaine universitaire du Sart Tilman

    Liège, Belgium

  • CHU UCL Namur site de Sainte Elisabeth

    Namur, Belgium

  • Fakultni Nemocnice Brno

    Brno, Czechia

  • Fakultni nemocnice Olomouc Onkologic

    Olomouc, Czechia

  • Vseobecna fakultni nemocnice v Praze

    Prague, Czechia

  • Nemocnice Na Bulovce, Gynekologicko-porodnicka kl

    Prague, Czechia

  • Aalborg Universitetshospital

    Aalborg, Denmark

  • Rigshospitalet

    Copenhagen, Denmark

  • Kliniken Essen-Mitte

    Düsseldorf, Germany

  • Universitaetsklinikum Hamburg-Eppendorf

    Hamburg, Germany

  • Klinikum der Universität München

    Münich, Germany

  • Policlinico S.Orsola-Malpighi, SSD Oncologia Medica Addarii

    Bologna, Italy

Showing 40 of 53 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.